

Amendments to the Claims

The following listing of claims replaces all prior listings and versions of claims in this application.

1. (Original) A clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemagglutinin-neuraminidase (HN) gene.
2. (Currently amended) A pharmaceutical composition for the treatment of cancer ~~consisting essentially of a replication-deficient~~ comprising the clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) according to claim 1, optionally in combination with a suitable carrier.
3. (Previously presented) The pharmaceutical composition according to claim 2 wherein the carrier is present.
4. (Currently amended) The composition according to claim 2 wherein the lentogenic strain of NDV is the HUI strain ~~having the nucleotide sequence of SEQ ID NO: 1~~.
5. (Previously presented) The composition according to claim 4 wherein the strain is present in an amount of $10^6 - 10^{12}$ EID₅₀ per unit dose.
6. (Withdrawn) The composition according to claim 2 in combination with at least one isolated viral glycoprotein having oncolytic activity.
7. (Withdrawn) The composition according to claim 6 wherein the at least one viral glycoprotein is from NDV.
8. (Withdrawn) The composition according to claim 7 wherein the at least one viral glycoprotein is the F glycoprotein of NDV.
9. (Withdrawn) The composition according to claim 7 wherein the at least one viral glycoprotein is the HN glycoprotein of NDV.
10. (Withdrawn) The composition according to claim 7 in combination with the F glycoprotein and hemagglutinin-neuraminidase (HN) glycoprotein of NDV.

11. (Withdrawn) The composition according to claim 7 wherein the viral glycoprotein is from a velogenic strain of NDV.
12. (Withdrawn) The composition according to claim 7 wherein the viral glycoprotein is from a mesogenic strain of NDV.
13. (Withdrawn) The composition according to claim 7 wherein the viral glycoprotein is from a lentogenic strain of NDV.
14. (Withdrawn) The composition according to claim 13 wherein the lentogenic strain of NDV is the HUI strain comprising the nucleotide sequence of SEQ ID NO: 1.

Claims 15 to 23. (Cancelled)

24. (Original) A method for treating cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 2.
25. (Original) The method of claim 24 wherein the step of administering is selected from intravenous, oral, buccal, intranasal, inhalation, topical application to a mucosal membrane or injection, including intradermal, intrathecal, intracisternal, and intralesional injection.
26. (Previously presented) The method of claim 24 wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.
27. (Cancelled)
28. (Currently amended) The method of claim 24 wherein the lentogenic oncolytic strain of NDV is the HUI strain ~~comprising the nucleotide sequence of SEQ ID NO: 1.~~
29. (Previously presented) The method of claim 28 wherein the strain is present in the composition in an amount of $10^6 - 10^{12}$ EID₅₀ per unit dose.
30. (Previously presented) The method of claim 28 wherein the step of administering comprises administering the HUI strain of NDV in a range of 20 EID₅₀/cell to 2000 EID₅₀/cell.

Claims 31 to 54. (Cancelled)

55. (Withdrawn) A method of making the pharmaceutical composition according to claim 2, which comprises incorporating in the composition the clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemagglutinin-neuraminidase (HN) at least one isolated polynucleotide of a replication-deficient Newcastle Disease Virus (NDV), the at least one isolated polynucleotide encoding at least one polypeptide of NDV having oncolytic activity.
56. (Withdrawn) The method according to claim 55 which further comprises incorporating at least one isolated viral glycoprotein having oncolytic activity in the composition.

Claims 57 to 65. (Cancelled)